May 10, 2019 13:34 JST
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
TOKYO, May 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan. Medac is marketing this product mainly in Europe and the United States.
Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan. Medac will submit a manufacturing and marketing authorization application for the product after conducting a clinical study in Japan. Once approved, Eisai will distribute the product. In accordance with the agreement, Eisai will pay Medac an upfront payment as well as developmental and sales milestone payments.
MTX is used as the first-line option for the treatment of rheumatic arthritis. However, it is known that its bioavailability shows significant interindividual variability in oral administration.(1) MTX subcutaneous injection which Eisai is in-licensing from Medac, is administered once a week via subcutaneous injection and enables a high bioavailability to be maintained. Furthermore, MTX subcutaneous injection has been reported to have a lower intensity of some gastrointestinal side effects than the oral drug.(2),(3)
It is reported that there are approximately 700,000 - 800,000 rheumatoid arthritis patients in Japan.(4) Eisai markets the anti-rheumatic agents HUMIRA and Careram in Japan, and has a wealth of clinical data and experience in the field of rheumatoid arthritis. With the addition of MTX subcutaneous injection as the first choice for rheumatoid arthritis treatment to these existing products, it will be possible to make a major contribution to the patients in wider treatment stages for rheumatoid arthritis including the initial treatment.
By providing MTX subcutaneous injection as a new option for use in drug therapy for rheumatoid arthritis, Eisai will make further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients and their families.
About Methotrexate Subcutaneous Injection
Methotrexate (MTX) is positioned as the anchor drug for rheumatoid arthritis treatment.(5) For rheumatoid arthritis, it is believed that MTX regulates cell growth by inhibiting folate metabolism in lymphocytes and other cells, and also has an anti-inflammatory mechanism through the promotion of adenosine synthesis in vascular endothelial cells and other cells in synovial membranes. The subcutaneous formulation is administered once a week via subcutaneous injection, which enables a high bioavailability to be maintained. Furthermore, MTX subcutaneous injection has been reported to have a lower intensity of some gastrointestinal side effects than the oral drug.(2),(3)
Medac is a pharmaceutical company located in Wedel, Germany (suburbs of Hamburg), specialized in the treatment and diagnosis of oncological, urological and autoimmune diseases since 1970, and we are very much aware of the particular requirements of these fields. We take responsibility for our actions and all our expertise is geared to the provision of qualitatively perfect and reliable products for patients, doctors, laboratory personnel and hospitals.
For more information about Medac, please visit https://www.medac.de(New Window) (available in German only)
(1) Lebbe C, et al. Ann Rheum Dis 1994; 53(7) 475-477
(2) Rutkowska-Sak L, et al. Reumatologia 2009; 47 (4) 207-211
(3) Cipriani P, et al. Clin Ther 2014; 36(3) 427-435
(4) Report from Study Committee on Rheumatoid Arthritis and Allergy
(5) Japan College of Rheumatology, Clinical practice guideline of methotrexate for patients with rheumatoid arthritis: 2016 update version
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit https://www.eisai.com
Public Relations Department,
Eisai Co., Ltd.
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Press Release
More Latest Release >>
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST
Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST
DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST
Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST
Mitsubishi Motors Announces Production, Sales and Export Figures for April 2020
May 28, 2020 19:09 JST
Honda Sets Monthly Records for Automobile Production in China
May 28, 2020 18:52 JST
Mazda Production and Sales Results for April 2020
May 28, 2020 16:46 JST
Mazda Joins IP Open Access Declaration Against Covid-19
May 28, 2020 16:28 JST
Toyota Releases Sales, Production, and Export Results for April 2020
May 28, 2020 13:56 JST
Fujitsu Accelerates Digital Transformation with Flexible, Scale-out Software-Defined Storage ETERNUS Data Services Platform
May 28, 2020 11:26 JST
Alliance New Cooperation Business Model to Support Member-Company Competitiveness and Profitability
May 27, 2020 18:28 JST
eK X and eK Wagon Achieve Top Ratings for Preventive and Collision Safety Performance in JNCAP
May 27, 2020 15:31 JST
2019 JNCAP Assessment on Toyota Vehicles Announced
May 27, 2020 14:07 JST
Fujitsu Launches 14 New Models of Enterprise Notebooks, Tablets and Workstations Optimized for Remote Work
May 26, 2020 11:10 JST
Fujitsu Develops AI-Video Recognition Technology to Promote Hand Washing Etiquette and Hygiene in the Workplace
May 26, 2020 10:34 JST
Mitsubishi Motors Joins OPEN COVID-19 DECLARATION
May 26, 2020 09:34 JST
Tokyo Metropolitan Government to trial 5G Antenna-equipped Smart Poles in Cooperation with Sumitomo Corporation and NEC
May 25, 2020 10:44 JST
Mazda Begins Providing, Virtual Racing Car, Mazda RX-Vision GT3 Concept Online
May 22, 2020 14:26 JST
'e5 Consortium' Established to Promote Zero-Emission Electric Vessel
May 21, 2020 15:34 JST